Investornewsbreaks Telomir Pharmaceuticals (NASDAQ: TELO) Advances Copper-Binding Drug For Wilson's Disease And Age-Related Therapies

(MENAFN- Investor Brand Network) Telomir Pharmaceuticals (NASDAQ: TELO) announced promising preclinical findings demonstrating the copper-binding capabilities of its Telomir-1 drug candidate, positioning it as a potential treatment for Wilson's disease and other copper-related disorders. Recent studies highlighted Telomir-1's ability to selectively bind and regulate copper, iron, and zinc, providing a foundation for addressing Wilson's disease, a rare genetic condition caused by toxic copper accumulation. The company also outlined its broader research initiatives, including studies on Type 2 diabetes, Alzheimer's disease, cancer, and metal toxicity. Telomir plans to file an IND application in late 2025, with human clinical trials targeted for 2026, aiming to revolutionize treatments for age-related diseases by addressing their root causes.

To view the full press release, visit

About Telomir Pharmaceuticals

Telomir Pharmaceuticals is a preclinical stage pharmaceutical company seeking to lead development in longevity science in both humans and animals. The company is focused on the development of
Telomir-1, a novel small molecule designed to lengthen the DNA's protective telomere caps, which are crucial in the aging process. Telomeres are the protective end caps of a chromosome made up of DNA sequences and proteins. As humans age, telomeres shorten, with metal reactivity accelerating the process, which presents humans and pet animals with an increased chance of contracting a number of degenerative and age-related diseases. Telomir's goal is to develop, gain regulatory approval for and commercialize Telomir-1, proposed to be dosed orally, with the broader aim of promoting longevity and enhancing overall quality of life. For more information about the company, visit the website
.

NOTE TO INVESTORS: The latest news and updates relating to TELO are available in the company's newsroom at

About InvestorWire

InvestorWire
(“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within
the
Dynamic Brand Portfolio
@
IBN
that delivers :
(1) access to a vast network of wire solutions via
InvestorWire
to efficiently and effectively reach a myriad of target markets, demographics and diverse industries ;
(2) article and
editorial syndication to 5,000+ outlets ;
(3) enhanced
press release enhancement
to ensure maximum impact ;
(4)
social media distribution
via IBN to millions of social media followers ;
and (5) a full array of tailored
corporate communications solutions . With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published:
/Disclaimer

InvestorWire
Los Angeles, CA

310.299.1717 Office
[email protected]

InvestorWire is powered by
IBN

MENAFN23122024000224011066ID1109024537